Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

API Manufacturing: SOP for Polymorph Screening Method – V 2.0

Posted on By

API Manufacturing: SOP for Polymorph Screening Method – V 2.0

Standard Operating Procedure for Polymorph Screening Method in API Manufacturing

Department API Manufacturing
SOP No. SOP/API/063/2025
Supersedes SOP/API/063/2022
Page No. Page 1 of 10
Issue Date 13/04/2025
Effective Date 15/04/2025
Review Date 13/04/2026

1. Purpose

To establish a standard and scientifically robust procedure for polymorph screening in API development and manufacturing to ensure the identification and control of solid-state forms of active pharmaceutical ingredients.

2. Scope

This SOP applies to all new and existing API compounds undergoing development, scale-up, or process optimization phases, where polymorphic behavior may impact stability, solubility, bioavailability, or regulatory requirements.

3. Responsibilities

  • R&D Scientists: Conduct polymorph screening experiments and interpret analytical data.
  • QC Department: Perform XRPD, DSC, and microscopy for solid-state characterization.
  • QA Department: Review reports and support documentation for regulatory submissions.
  • Technology Transfer Team: Ensure screened polymorph is consistently reproduced in plant batches.
See also  API Manufacturing: SOP for Cleaning Validation Between Batches - V 2.0

4. Accountability

The R&D Head is accountable for execution and documentation of polymorph screening. The QA Head is responsible for review and archival of polymorph data.

5. Procedure

5.1 Selection of Solvents and Conditions

  1. Select a panel of solvents based on polarity (e.g., water, methanol, acetone, toluene, ethyl acetate, hexane).
  2. Include binary/ternary solvent mixtures to expand screening coverage.
  3. Study cooling, evaporation, and slurry equilibration as crystallization techniques.

5.2 Experimental Execution

  1. Prepare saturated or near-saturated solutions of the API in selected solvents.
  2. Initiate crystallization using:
    • Cooling (e.g., from 60°C to 5°C)
    • Evaporation (at ambient or reduced pressure)
    • Slurry equilibration (for conversion studies)
  3. Maintain each experiment for a minimum of 24–72 hours for complete crystallization or transformation.
  4. Collect solid samples, filter, and dry at controlled temperature (e.g., 40°C for 6 hours).
See also  API Manufacturing: SOP for Labeling of Recovered Solvents with Batch Information - V 2.0

5.3 Analytical Evaluation

  1. Perform the following analyses:
    • XRPD: X-ray Powder Diffraction for crystal form identification
    • DSC: Differential Scanning Calorimetry for melting behavior
    • TGA: Thermogravimetric Analysis if solvates/hydrates are expected
    • Microscopy: Crystal morphology under polarizing microscope
    • FTIR: To detect conformational polymorphs (if applicable)
  2. Compare all results with reference standards or previously established polymorphic forms.

5.4 Documentation and Interpretation

  1. Document all data in “Polymorph Screening Summary Log” (Annexure-1).
  2. Summarize key findings in a “Polymorph Screening Report” including:
    • Polymorph form(s) obtained
    • Stability observation (if tested)
    • Preferred crystallization conditions
  3. Route the selected polymorph and its control strategy into process development.

6. Abbreviations

  • XRPD: X-Ray Powder Diffraction
  • DSC: Differential Scanning Calorimetry
  • TGA: Thermogravimetric Analysis
  • SOP: Standard Operating Procedure
  • API: Active Pharmaceutical Ingredient
  • QC: Quality Control
  • QA: Quality Assurance
See also  API Manufacturing: SOP for Prevention of Cross Contamination during Drying - V 2.0

7. Documents

  1. Polymorph Screening Summary Log (Annexure-1)
  2. Polymorph Screening Report
  3. Analytical Raw Data (XRPD, DSC, etc.)

8. References

  • ICH Q6A – Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and Products
  • FDA Guidance on ANDAs: Pharmaceutical Solid Polymorphism
  • Internal Polymorph Study Guidelines

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Polymorph Screening Summary Log

Date API Name Solvent Method Polymorph Observed Remarks
13/04/2025 API-A Acetone Cooling Form I Matched with Reference

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial SOP Release New Polymorph Control Program QA Head
13/04/2025 2.0 Added Binary Solvent System Screening Project Expansion QA Head
API Manufacturing V 2.0 Tags:API batch record, API BMR, API calibration, API centrifuge, API cleaning, API crystallization, API deviation, API documentation, API drying, API equipment cleaning, API filtration, API GMP compliance, API granulation, API hold time, API impurities, API line clearance, API manufacturing, API process, API quality control, API reactor, API sampling, API solvent handling, API validation, API waste disposal, API yield

Post navigation

Previous Post: Elixir Department: SOP for Control of Cross-Contamination During Dispensing – V 2.0
Next Post: BA-BE Studies: SOP for Conducting Mock Runs for BA/BE – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version